Analyst Reco. Alnylam Pharmaceuticals, Inc. Börse Stuttgart

Equities

DUL

US02043Q1076

Real-time Estimate Tradegate Other stock markets 05:41:17 2024-06-28 EDT			5-day change	1st Jan Change
230.7 ^EUR	-0.13%		+59.42%	+31.55%

06-27	Stifel Adjusts Price Target on Alnylam Pharmaceuticals to $295 From $215, Maintains Buy Rating	MT
06-27	RBC Raises Price Target on Alnylam Pharmaceuticals to $265 From $250, Keeps Outperform Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Stifel Adjusts Price Target on Alnylam Pharmaceuticals to $295 From $215, Maintains Buy Rating	06-27	MT
RBC Raises Price Target on Alnylam Pharmaceuticals to $265 From $250, Keeps Outperform Rating	06-27	MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $370,747, According to a Recent SEC Filing	06-26	MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,917,475, According to a Recent SEC Filing	06-26	MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $485,773, According to a Recent SEC Filing	06-26	MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $7,161,360, According to a Recent SEC Filing	06-26	MT
TD Cowen Adjusts Price Target on Alnylam Pharmaceuticals to $282 From $260, Maintains Buy Rating	06-25	MT
Barclays Raises Price Target on Alnylam Pharmaceuticals to $291 From $236, Maintains Overweight Rating	06-25	MT
Wells Fargo Raises Price Target on Alnylam Pharmaceuticals to $207 From $161, Maintains Equalweight Rating	06-25	MT
Morgan Stanley Raises Alnylam Pharmaceuticals Price Target to $250 From $164, Maintains Equal Weight Rating	06-25	MT
Evercore ISI Boosts Price Target on Alnylam Pharmaceuticals to $260 From $210, Keeps Outperform Rating	06-25	MT
Chardan Raises Price Target on Alnylam Pharmaceuticals to $265 From $225, Keeps Buy Rating	06-25	MT
RBC Raises Price Target on Alnylam Pharmaceuticals to $250 From $235, Keeps Outperform Rating	06-25	MT
ANALYST RECOMMENDATIONS : Capri Holdings, Adobe, Broadcom, Celanese, Admiral...	06-25
Alnylam Pharmaceuticals Insider Sold Shares Worth $3,224,546, According to a Recent SEC Filing	06-03	MT
HC Wainwright Adjusts Price Target on Alnylam Pharmaceuticals to $400 From $395, Maintains Buy Rating	05-07	MT
ANALYST RECOMMENDATIONS : Chevron, Take-Two, Coinbase, Netflix, American Tower...	04-08
ANALYST RECOMMENDATIONS : AbbVie, Doordash, Eli Lilly, Moderna, Hiscox...	02-26
ANALYST RECOMMENDATIONS : Airbnb, Conagra Brands, Berkshire Hathaway, Meta Platforms, Unilever....	02-21
Chardan Cuts Price Target on Alnylam Pharmaceuticals to $225 From $250, Expects Topline Results in Mid-2024, Maintains Buy Rating	02-16	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Alnylam Pharmaceuticals, Inc. Börse Stuttgart

Equities

DUL

US02043Q1076

Analyst Reco.

Filters